Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mathematical Modeling Reveals the Correlates of Cognitive Impairment Across the FTLD Spectrum
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
024
The aim of this study was to apply mathematical modeling to unravel MRI connectomic signatures of cognitive and/or behavioral impairment in amyotrophic lateral sclerosis (ALS) patients.

Patients with ALS, characterized by motor system degeneration, can also develop cognitive and/or behavioural symptoms that lie on a continuum with the behavioral variant of frontotemporal dementia (bvFTD).

Eighty-three ALS, 35 bvFTD and 61 controls underwent clinical/cognitive evaluations and MRI scan. ALS patients were classified in 54 ALS pure-motor (ALSpm), 21 ALS with cognitive/behavioural impairment (ALSci/bi) and 8 ALS with FTD (ALS-FTD). The structural value of the brain connections was considered and normalized relative to controls. Statistical distribution analysis was performed to identify structural patterns between bvFTD and ALSpm and to assess ALS-like or a bvFTD-like patterns in ALSci/bi and ALS-FTD.

Compared to ALSpm, bvFTD showed greater structural involvement of the connections within and between frontal, temporal and parietal lobes. Conversely, ALSpm patients showed greater involvement of the connections between sensorimotor and basal ganglia areas, compared with bvFTD. ALSci/bi and ALS-FTD showed an ALSpm-like pattern within sensorimotor and basal ganglia areas. Within the frontotemporoparietal networks ALSci/bi and ALS-FTD behaved differently: ALSci/bi showed a bvFTD-like pattern only within the parietotemporal connections, while ALS-FTD showed a bvFTD-like pattern also within frontal and between frontal and sensorimotor areas.

This study showed a widespread structural damage in bvFTD, particularly in the connections within frontotemporal areas and between frontal and other lobes, and a more focal structural damage within sensorimotor-basal ganglia areas in ALSpm. ALSci/bi and ALS-FTD showed an ALS-like pattern with the exception of a greater damage within the frontal and parietotemporal areas, signature of the occurrence of cognitive impairment.

Authors/Disclosures
Camilla Cividini, MSc (San Raffaele Scientific Institute, Vita-Salute San Raffaele University)
PRESENTER
Ms. Cividini has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Silvia Basaia Silvia Basaia has nothing to disclose.
Edoardo G. Spinelli, MD Dr. Spinelli has nothing to disclose.
Veronica Castelnovo, MSc (San Raffaele Scientific Institute, Vita-Salute San Raffaele University) Dr. Castelnovo has nothing to disclose.
Elisa Canu (Ospedale San Raffaele) The institution of Elisa Canu has received research support from Italian Ministry of Health .
No disclosure on file
Giuseppe Magnani Giuseppe Magnani has nothing to disclose.
Francesca Caso, MD (Universita' Vita Salute San Raffaele) Dr. Caso has nothing to disclose.
Massimo Filippi, MD, FÂé¶¹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.